A successful Type B Rare Disease Evidence Principles meeting confirms the pivotal study design, opening a potential BLA pathway on 6-month efficacy data, with dosing expected to begin in the fourth quarter of 2026.
|Podcasts|February 23, 2022
The changing landscape of gene therapy and standardized endpoints
Author(s)David Hutton
In this episode of EyePod, Ora Clinical’s Keith Lane offers a brief overview of the current state of ophthalmology and its standardized endpoints. He also discusses some of the challenges that gene therapy has faced, particularly in relation to ophthalmology. He also offers his outlook for the future of gene therapy.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
2
Alvotech files first known aflibercept 8 mg biosimilar with EMA
3
FDA approves subcutaneous Enspryng for TED
4
Beyond slowing atrophy: Optogenetic therapy targets vision lost to GA
5